Allegra Rollo

Allegra Rollo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMay-Tal Sauerbrun-Cutler
May-Tal Sauerbrun-Cutler
ARAllegra Rollo
Allegra Rollo
AGAlexis K. Gadson
Alexis K. Gadson
JEJennifer L. Eaton
Jennifer L. Eaton
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.

13 December 2025 in Urology
Verified
Journal Article
Closed access
ELEmma Laquinta
Emma Laquinta
ARAllegra Rollo
Allegra Rollo
ASAaron Seto
Aaron Seto
TBTaylor Braunagel
Taylor Braunagel
KMKamil Malshy
Kamil Malshy
MCMadeline Cancian
Madeline Cancian

21 October 2024 in Fertility and Sterility
Verified
Journal Article
Closed access
MSMay-Tal Sauerbrun-Cutler
May-Tal Sauerbrun-Cutler
FMFarahnaz Maroof
Farahnaz Maroof
ARAllegra Rollo
Allegra Rollo
ZYZexuan Yu
Zexuan Yu
CSChristopher Schmid
Christopher Schmid
ECElizabeth S. Chen
Elizabeth S. Chen

29 September 2026 in Journal of Law, Medicine & Ethics
Verified
Journal Article
Open access
PDF file
ARAllegra Rollo
Allegra Rollo
SSShelly Simana
Shelly Simana
EAEli Y Adashi
Eli Y Adashi
The litigation brought by the Estate of Henrietta Lacks against Thermo Fisher Scientific, Ultragenyx Pharmaceutical, and Novartis Pharmaceuticals reframes benefit-sharing from voluntary institutional ethics into an enforceable legal duty. By pleading a single equitable claim — unjust enrichment — the Estate seeks to bypass the property and informed-consent doctrines that have defeated comparable tissue-appropriation suits, while accepting distinctive risks involving remoteness, limitations, causation, and apportionment. This commentary examines the strategy’s strengths and vulnerabilities through the still-pending Ultragenyx case, and considers its implications for research consent, prospective benefit-sharing frameworks, and bioethics pedagogy. Whether or not the remaining claim succeeds, the litigation has already altered the conversation about who should profit from human biological materials.